Andrea Scotti1,2, MD; Matteo Pagnesi3, MD; Won-Keun Kim4, MD; Ulrich Schäfer5, MD; Marco Barbanti6, MD; Giuliano Costa6, MD; Sara Baggio7, MD; Matteo Casenghi8, MD; Federico De Marco8, MD; Maarten Vanhaverbeke9, MD, PhD; Lars Søndergaard9, MD; Alexander Wolf10, MD; Joachim Schofer11, MD; Marco Bruno Ancona12, MD; Matteo Montorfano12, MD; Ran Kornowski13, MD; Hana Vaknin Assa13, MD; Stefan Toggweiler14, MD; Alfonso Ielasi15, MD; David Hildick-Smith16, MD; Stephan Windecker17, MD; Albrecht Schmidt18, MD; Andrea Buono19, MD; Diego Maffeo19, MD; Dimytri Siqueira20, MD; Francesco Giannini21, MD; Marianna Adamo3, MD; Mauro Massussi3, MD; David A. Wood22, MD; Jan-Malte Sinning23, MD; Jan Van der Heyden24, MD; Dirk-Jan van Ginkel25, MD; Nicholas Van Mieghem26, MD; Verena Veulemans27, MD; Darren Mylotte28, MD; Vasileios Tzalamouras29, MD; Maurizio Taramasso30, MD; Rodrigo Estévez-Loureiro31, MD, PhD; Antonio Colombo7, MD; Antonio Mangieri7, MD; Azeem Latib1, MD
1. Montefiore Einstein Center for Heart and Vascular Care, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA; 2. Cardiovascular Research Foundation, New York, NY, USA; 3. ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy; 4. Department of Cardiology and Cardiac Surgery, Kerckhoff Heart and Lung Center, Bad Nauheim, Germany; 5. Department of Cardiology, University Heart & Vascular Center, Hamburg, Germany; 6. Department of Cardiology, C.A.S.T. Policlinic G. Rodolico Hospital, University of Catania, Catania, Italy; 7. Cardio Center, Humanitas Research Hospital, Rozzano-Milan, Italy; 8. Department of Cardiology, IRCCS Policlinico San Donato, Milan, Italy; 9. The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; 10. Contilia Heart and Vascular Centre, Elisabeth-Krankenhaus Essen, Essen, Germany; 11. Department for Percutaneous Treatment of Structural Heart Disease, Albertinen Heart Center, Hamburg, Germany; 12. Cardio-Thoracic-Vascular Department, San Raffaele Scientific Institute, Milan, Italy; 13. Department of Cardiology, Rabin Medical Center-Beilinson Hospital, Petah Tikva, Israel; 14. Department of Cardiology, Heart Center Lucerne, Luzerner Kantonsspital, Lucerne, Switzerland; 15. Clinical and Interventional Cardiology Unit, Istituto Clinico Sant'Ambrogio, Milan, Italy; 16. Department of Cardiology, Royal Sussex County Hospital, Brighton, United Kingdom; 17. Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; 18. Division of Cardiology, Medical University of Graz, Graz, Austria; 19. Interventional Cardiology Unit, Fondazione Poliambulanza, Brescia, Italy; 20. Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil; 21. GVM Care and Research, Maria Cecilia Hospital, Cotignola, Italy; 22. Centre for Heart Valve Innovation, St. Paul’s and Vancouver General Hospital, Vancouver, BC, Canada; 23. Department of Cardiology, Heart Center Bonn, University Hospital Bonn, Bonn, Germany; 24. Sint-Jan Hospital, Bruges, Belgium; 25. Department of Cardiology, St Antonius Hospital, Nieuwegein, the Netherlands; 26. Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands; 27. Division of Cardiology, Pulmonology, and Vascular Medicine, University Hospital Düsseldorf, Düsseldorf, Germany; 28. Department of Cardiology, Galway University Hospital, Galway, Ireland; 29. Cardiology, King's College Hospital, London, United Kingdom; 30. Division of Cardiothoracic Surgery, Arzt bei HerzZentrum Hirslanden Zürich, Zürich, Switzerland; 31. Cardiology Department, University Hospital Alvaro Cunqueiro, Galicia Sur Health Research Institute, Vigo, Spain
Background: Transcatheter aortic valve replacement (TAVR) with the ACURATE neo device has been associated with a non-negligible incidence of paravalvular aortic regurgitation (AR). The new-generation ACURATE neo2 has been designed to mitigate this limitation.
Aims: The aim of the study was to compare TAVR with the ACURATE neo and neo2 devices.
Methods: The NEOPRO and NEOPRO-2 registries retrospectively included patients undergoing transfemoral TAVR with self-expanding valves at 24 and 20 centres, respectively. Patients receiving the ACURATE neo and neo2 devices (from January 2012 to December 2021) were included in this study. Predischarge and 30-day VARC–3 defined outcomes were evaluated. The primary endpoint was predischarge moderate or severe paravalvular AR. Subgroup analyses per degree of aortic valve calcification were performed.
Results: A total of 2,026 patients (neo: 1,263, neo2: 763) were included. Predischarge moderate or severe paravalvular AR was less frequent for the neo2 group (2% vs 5%; p<0.001), resulting in higher VARC-3 intended valve performance (96% vs 90%; p<0.001). Furthermore, more patients receiving the neo2 had none/trace paravalvular AR (59% vs 38%; p<0.001). The reduction in paravalvular AR with neo2 was mainly observed with heavy aortic valve calcification. New pacemaker implantation and VARC-3 technical and device success rates were similar between the 2 groups; there were more frequent vascular and bleeding complications for the neo device. Similar 1-year survival was detected after TAVR (neo2: 90% vs neo: 87%; p=0.14).
Conclusions: TAVR with the ACURATE neo2 device was associated with a lower prevalence of moderate or severe paravalvular AR and more patients with none/trace paravalvular AR. This difference was particularly evident with heavy aortic valve calcification.
No account yet? Create my pcr account
Sign up for free!
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases
aortic stenosisatrio-ventricular blockconduction abnormalitiestavr
Read next article
Antithrombotic strategy variability in atrial fibrillation and obstructive coronary disease revascularised with percutaneous coronary intervention: primary results from the AVIATOR 2 international registry